Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
WILMINGTON, Del., March 07, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of GW Pharmaceuticals plc (NASDAQ:GWPH)?
- Did you purchase your shares between December 4, 2014 and January 8, 2016, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of GW Pharmaceuticals plc (“GW Pharmaceuticals” or the “Company”) (NASDAQ:GWPH) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the Southern District of New York on behalf of all persons or entities that purchased the American Depository Receipts (“ADRs”) of GW Pharmaceuticals between December 4, 2014 and January 8, 2016, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you wish to serve as lead plaintiff, you must move the Court no later than March 21, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased ADRs of GW Pharmaceuticals during the Class Period, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/gw-pharmaceuticals-plc-gwph.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
